Ignacio Garrido-Laguna

Ignacio Garrido-Laguna

UNVERIFIED PROFILE

Are you Ignacio Garrido-Laguna?   Register this Author

Register author
Ignacio Garrido-Laguna

Ignacio Garrido-Laguna

Publications by authors named "Ignacio Garrido-Laguna"

Are you Ignacio Garrido-Laguna?   Register this Author

59Publications

1090Reads

14Profile Views

The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer.

Cancer Med 2020 Mar 16;9(5):1703-1711. Epub 2020 Jan 16.

Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, UT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2851DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050091PMC
March 2020

From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.

Nat Rev Clin Oncol 2020 Feb 8;17(2):108-123. Epub 2019 Nov 8.

Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0281-6DOI Listing
February 2020

Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy.

J Gastrointest Surg 2019 Jul 5;23(7):1401-1413. Epub 2018 Sep 5.

Division of General Surgery, Department of Surgery, University of Utah, 30 North 1900 East, Salt Lake City, UT, 84132, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11605-018-3953-0DOI Listing
July 2019

Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle.

J Gastrointest Oncol 2018 Dec;9(6):1014-1026

Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jgo.2018.05.16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286952PMC
December 2018

TIGIT: a novel immunotherapy target moving from bench to bedside.

Cancer Immunol Immunother 2018 Nov 19;67(11):1659-1667. Epub 2018 Sep 19.

Oncology Division, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, 2000 Circle of Hope, Suite 2100, Salt Lake City, UT, 84112, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-018-2246-5DOI Listing
November 2018

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 08 23;36(24):2545-2556. Epub 2018 May 23.

Davendra P.S. Sohal, Alok Khorana, and Smitha Krishnamurthi, Cleveland Clinic, Cleveland OH; Erin B. Kennedy, American Society of Clinical Oncology, Alexandria, VA; Mehmet S. Copur, CHI Health St. Francis Cancer Treatment Center, Grand Island, NE; Christopher H. Crane, The University of Texas MD Anderson Cancer Center, Houston, TX; Ignacio Garrido-Laguna, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT; Cassadie Moravek, Pancreatic Cancer Action Network, Manhattan Beach, CA; Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center; Joseph T. Ruggiero and Manish A. Shah, New York-Presbyterian/Weill Cornell Medical Center, New York, NY; Philip A. Philip, Barbara Ann Karmanos Cancer Institute, Farmington Hills; Susan Urba, University of Michigan Health System Comprehensive Cancer Center, Ann Arbor, MI; Ramesh K. Ramanathan, Mayo Clinic; Michelle W. Lau, Phoenix VA Medical Center, Phoenix, AZ; Hope E. Uronis, Duke University, Durham, NC; and Daniel Laheru, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.9636DOI Listing
August 2018

Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.

Future Oncol 2018 Apr 15;14(10):947-962. Epub 2018 Mar 15.

Department of Internal Medicine (Division of Oncology), University of Utah School of Medicine, Salt Lake City, UT 84103, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2017-0597
Publisher Site
http://dx.doi.org/10.2217/fon-2017-0597DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925434PMC
April 2018

Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins.

ESMO Open 2018 27;3(1):e000282. Epub 2018 Jan 27.

Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2017-000282DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786921PMC
January 2018

Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis.

Ann Surg Oncol 2017 Dec 17;24(13):4001-4008. Epub 2017 Oct 17.

Department of Radiation Oncology, University of Utah, Salt Lake City, UT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-017-6131-9DOI Listing
December 2017

Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer.

Cancer 2017 Oct 16;123(19):3816-3824. Epub 2017 Jun 16.

Department of Radiation Oncology, Intermountain Medical Center, Murray, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30780DOI Listing
October 2017

Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma.

Immunotherapy 2017 09;9(10):797-804

Department of Hematology and Oncology, University of Utah School of Medicine, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT 84112, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt-2017-0042
Publisher Site
http://dx.doi.org/10.2217/imt-2017-0042DOI Listing
September 2017

Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.

J Gastrointest Oncol 2017 Jun;8(3):387-404

Center for Investigational Therapeutics, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jgo.2017.01.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506274PMC
June 2017

A 30-Year-Old Man with Three Primary Malignancies: A Case of Constitutional Mismatch Repair Deficiency.

ACG Case Rep J 2017 1;4:e34. Epub 2017 Mar 1.

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Division of Gastroenterology and Hepatology, University of Utah, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/crj.2017.34DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340720PMC
March 2017

Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue.

Clin Neurol Neurosurg 2016 Oct 14;149:11-4. Epub 2016 Jul 14.

University of Utah, Department of Neurology, Salt Lake City, UT, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03038467163019
Publisher Site
http://dx.doi.org/10.1016/j.clineuro.2016.05.023DOI Listing
October 2016

Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.

Mol Cancer Ther 2016 04 23;15(4):533-47. Epub 2016 Mar 23.

Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0643DOI Listing
April 2016

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer.

Onco Targets Ther 2016 30;9:75-86. Epub 2015 Dec 30.

Department of Internal Medicine, Oncology Division and Center for Investigational Therapeutics, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S68558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706127PMC
January 2016

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.

Nat Rev Clin Oncol 2015 Jun 31;12(6):319-34. Epub 2015 Mar 31.

Gastrointestinal Cancer Clinical Research Unit, Clinical Research Program, Spanish National Cancer Research Centre (CNIO), Calle de Melchor Fernández Almagro 3, 28029 Madrid, Spain.

View Article

Download full-text PDF

Source
http://www.nature.com/nrclinonc/journal/v12/n6/pdf/nrclinonc
Web Search
http://dx.doi.org/10.1038/nrclinonc.2015.53DOI Listing
June 2015

N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012.

Oncoscience 2015 14;2(3):285-93. Epub 2015 Mar 14.

Departments of Internal Medicine (Division of Oncology), Huntsman Cancer Institute and University of Utah School of Medicine, Salt Lake City ; Center for Investigational Therapeutics, Huntsman Cancer Institute and University of Utah School of Medicine, Salt Lake City.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394134PMC
http://dx.doi.org/10.18632/oncoscience.141DOI Listing
April 2015

Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies.

Discov Med 2015 Feb;19(103):101-8

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
February 2015

Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome.

Discov Med 2015 Feb;19(103):109-16

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
February 2015

A framework for genomic biomarker actionability and its use in clinical decision making.

Oncoscience 2014 22;1(10):614-623. Epub 2014 Oct 22.

Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego, California, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278279PMC
http://dx.doi.org/10.18632/oncoscience.90DOI Listing
January 2015

Epidemiology and familial risk of synchronous and metachronous colorectal cancer: a population-based study in Utah.

Clin Gastroenterol Hepatol 2014 Dec 24;12(12):2078-84.e1-2. Epub 2014 Apr 24.

Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; Department of Medicine (Gastroenterology), University of Utah, Salt Lake City, Utah; Department of Oncological Sciences, University of Utah, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15423565140060
Publisher Site
http://dx.doi.org/10.1016/j.cgh.2014.04.017DOI Listing
December 2014

Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX.

J Gastrointest Cancer 2014 Dec;45 Suppl 1:278-81

Department of Internal Medicine (Division of Oncology) and Center for Investigational Therapeutics, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Suite 2100, Salt Lake City, UT, 84112, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12029-014-9662-3DOI Listing
December 2014

Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.

Discov Med 2014 Dec;18(101):323-30

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
December 2014

Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience.

Clin Colorectal Cancer 2012 Dec 25;11(4):297-303. Epub 2012 Apr 25.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2012.02.001DOI Listing
December 2012

PIK3CA mutations in advanced cancers: characteristics and outcomes.

Oncotarget 2012 Dec;3(12):1566-75

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681495PMC
http://dx.doi.org/10.18632/oncotarget.716DOI Listing
December 2012

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.

PLoS One 2012 31;7(5):e38033. Epub 2012 May 31.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0038033PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364990PMC
September 2012

Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.

Cancer 2012 Mar 5;118(5):1422-8. Epub 2011 Aug 5.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26413DOI Listing
March 2012

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

PLoS One 2011 29;6(7):e22769. Epub 2011 Jul 29.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0022769PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146490PMC
December 2011

Novel therapeutic targets in non-small cell lung cancer.

J Thorac Oncol 2011 Sep;6(9):1601-12

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155608641531339
Publisher Site
http://dx.doi.org/10.1097/JTO.0b013e31822944b3DOI Listing
September 2011

Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.

Oncologist 2011 21;16(3):327-35. Epub 2011 Feb 21.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2010-0308DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228100PMC
August 2011

The inverted pyramid of biomarker-driven trials.

Nat Rev Clin Oncol 2011 08 2;8(9):562-6. Epub 2011 Aug 2.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2011.113
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2011.113DOI Listing
August 2011

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Mol Cancer Ther 2011 Mar 7;10(3):558-65. Epub 2011 Jan 7.

Department of Investigational Cancer Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., FC8.2057, Box 0455, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-10-0994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072168PMC
March 2011

Response of histiocytoses to imatinib mesylate: fire to ashes.

J Clin Oncol 2010 Nov 23;28(31):e633-6. Epub 2010 Aug 23.

The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.29.9073DOI Listing
November 2010

Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.

Clin Cancer Res 2010 Aug 4;16(15):4031-7. Epub 2010 Jun 4.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), University of Texas M.D. Anderson Cancer Center, 1515Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-0672DOI Listing
August 2010

New scaffolds for the design of selective estrogen receptor modulators.

Org Biomol Chem 2008 Oct 4;6(19):3486-96. Epub 2008 Aug 4.

Departamento de Química, Facultad de Farmacia, Universidad San Pablo CEU, 28668-Boadilla del Monte, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/b806918bDOI Listing
October 2008

MRI evaluation of breast cancer.

N Engl J Med 2007 Jul;357(2):191; author reply 193

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc071183DOI Listing
July 2007